Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients with moderately to severely active ulcerative colitis.
The Canadian Drug Expert Committee has recommended that ustekinumab be reimbursed for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contra-indications to such therapies, only if certain conditions are met.
Patients must have achieved clinical response to induction therapy within eight weeks for reimbursement of treatment with ustekinumab to continue to maintenance therapy.
